Mast Cell Activation Syndrome: A Review
- 4.9k Downloads
Mast cell activation syndrome (MCAS) is a condition with signs and symptoms involving the skin, gastrointestinal, cardiovascular, respiratory, and neurologic systems. It can be classified into primary, secondary, and idiopathic. Earlier proposed criteria for the diagnosis of MCAS included episodic symptoms consistent with mast cell mediator release affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope or near syncope, tachycardia, wheezing, conjunctival injection, pruritus, and nasal stuffiness. Other criteria included a decrease in the frequency, severity, or resolution of symptoms with anti-mediator therapy including H1 and H2histamine receptor antagonists, anti-leukotrienes, or mast cell stabilizers. Laboratory data that support the diagnosis include an increase of a validated urinary or serum marker of mast cell activation (MCA), namely the documentation of an increase of the marker above the patient’s baseline value during symptomatic periods on more than two occasions, or baseline serum tryptase levels that are persistently above 15 ng/ml, or documentation of an increase of the tryptase level above baseline value on one occasion. Less specific assays are 24-h urine histamine metabolites, PGD2 (Prostaglandin D2) or its metabolite, 11-β-prostaglandin F2 alpha. A recent global definition, criteria, and classification include typical clinical symptoms, a substantial transient increase in serum total tryptase level or an increase in other mast cell derived mediators, such as histamine or PGD2 or their urinary metabolites, and a response of clinical symptoms to agents that attenuate the production or activities of mast cell mediators.
KeywordsMast cell activation Mast cell activation syndrome Mastocytosis Idiopathic anaphylaxis Clonal MCAD Nonclonal MCAD Classification Treatment
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.Meninger CJ, Yano H, Rottapel R, et al. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood. 1992;4:958–63.Google Scholar
- 13.Bai Y, Bandara G, Ching Chan E. Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia. 2012. doi: 10.1038.
- 14.Bax HJ, Keeble AH, Gould HJ. Cytokinergic IgE action in mast cell activation. Front Immunol Inflamm Vol; 2012 (3) 8Google Scholar
- 15.•• Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099–104. This excellent paper explored and proposed criteria for the diagnosis of the mast cell activation syndrome. The proposed criteria was discussed in the context of other disorders involving mast cells or with similar presentations and as a basis for further scientific study and validation. PubMedCrossRefGoogle Scholar
- 17.Frieri M. Mastocytosis. In: Massoud Mahmoud editor. Challenging Cases in Allergy and Immunology, Chapter 14. Humana Press; 2009. pp 201–212.Google Scholar
- 20.An Updated Practice Parameter. In: Lieberman P et al., editor. Idiopathic Anaphylaxis. The Diagnosis and Management of Anaphylaxis. 2005;115; 3:S483–S523.Google Scholar
- 21.• Frieri M. Anaphylaxis. Chapter 68. In: Manual of critical care. Philadelphia: American College of Physicians; 2009. p. 721–30. This chapter reviewed the etiology, incidence, unusual manifestations, differential diagnosis, pathogenesis, prevention and treatment of anaphylaxis with a comprehensive table of mast cell and basophil mediators and clinical findings in anaphylaxis and anaphylactoid reactions. Google Scholar
- 27.•• Valent P, Akin C, Arock M, et al. Definitions, criteria & global classification of MC disorders with special reference to MCAS: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–25. This excellent paper proposed a global unifying classification of all MC disorders and pathologic MC reactions which included three types of 'MCA syndromes' (MCASs), namely primary MCAS, secondary MCAS, and idiopathic MCAS. It assisted in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or over interpretation of clinical symptoms in daily practice. PubMedCrossRefGoogle Scholar
- 31.Patel R, Celestin J, Frieri M. An unusual case of mast cell activation syndrome. J Allergy Clin Immunol, abs #475, 2012.Google Scholar